Search

Your search keyword '"Hurbin, A."' showing total 484 results
Start Over Author "Hurbin, A."
484 results on '"Hurbin, A."'

2. Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis

Author

Weidinger, Stephan, Blauvelt, Andrew, Papp, Kim A., Reich, Adam, Lee, Chih-Hung, Worm, Margitta, Lynde, Charles, Kataoka, Yoko, Foley, Peter, Wei, Xiaodan, Wong, Wanling, Solente, Anne-Catherine, Weber, Christine, Adelman, Samuel, Davey, Sonya, Hurbin, Fabrice, Rynkiewicz, Natalie, Yen, Karl, O’Malley, John T., and Bernigaud, Charlotte

Published
2024
Full Text
View/download PDF

4. Engineering Radiocatalytic Nanoliposomes with Hydrophobic Gold Nanoclusters for Radiotherapy Enhancement.

Author

Carigga Gutierrez, Nazareth Milagros, Clainche, Tristan Le, Bulin, Anne‐Laure, Leo, Sofia, Kadri, Malika, Abdelhamid, Ahmed Gamal Ali, Pujol‐Solé, Núria, Obaid, Girgis, Hograindleur, Marc‐André, Gardette, Vincent, Busser, Benoit, Motto‐Ros, Vincent, Josserand, Véronique, Henry, Maxime, Sancey, Lucie, Hurbin, Amandine, Elleaume, Hélène, Kandiah, Eaazhisai, Guével, Xavier Le, and Coll, Jean‐Luc

Published
2024
Full Text
View/download PDF

5. Transitions to food democracy through multilevel governance

Author

Anant Jani, Andreas Exner, Reiner Braun, Brigitte Braun, Luisa Torri, Sofie Verhoeven, Anna Maria Murante, Stefanie Van Devijvere, Janas Harrington, Amalia Ochoa, Giorgia Dalla Libera Marchiori, Peter Defranceschi, Aditi Bunker, Till Bärnighausen, Esther Sanz Sanz, Claude Napoléone, Eric O. Verger, Christian Schader, Joacim Röklov, Ingrid Stegeman, Samuele Tonello, Robert Pederson, Niels Heine Kristensen, Tim Smits, Dirk Wascher, Peter Voshol, Annemarie Kaptejins, Samantha Nesrallah, Olav Kjørven, Fabrice DeClerck, Cristina Biella, Marija Adela Gjorgjioska, Ana Tomicic, Ana Teresa Ferreira Oliveira, Stefania Bracco, Sandra Estevens, Luigi Rossi, Günther Laister, Aleksandra Różalska, Borche Jankuloski, Christophe Hurbin, Maýlis Jannic, Fiona Steel, Ewoud Manbaliu, Karin De Jager, Athanasios Sfetsos, Maria Konstantopoulou, Pavlos-Alexandro Kapetanakis, Michaela Hickersberger, Elsa Chiffard, and Carina Woollhead

Subjects
food systems, food democracy, multilevel governance, just transitions, health, sustainability, Nutrition. Foods and food supply, TX341-641, Food processing and manufacture, TP368-456
Abstract

Food systems in Europe are largely unjust and not sustainable. Despite substantial negative consequences for individual health, the environment and public sector health and care services, large multi-national corporations continue to benefit from the way food systems are designed—perpetuating “Lose–Lose–Lose–Win” food systems that see these large corporations benefit at the expense of health, the environment and public sector finances. Transitioning to “Win–Win–Win–Win” food systems is challenging because of the heterogeneity, complexity and unpredictable nature of food systems—one-size fits-all solutions to correct imbalances and injustices cannot exist. To address these challenges, we propose the use of heuristics—solutions that can flexibly account for different contexts, preferences and needs. Within food systems, food democracy could be a heuristic solution that provides the processes and can form the basis for driving just transitions. However, ensuring that these transition processes are fair, equitable, sustainable and constructive, requires an approach that can be used across vertical and horizontal governance spheres to ensure the voices of key stakeholders across space, time and spheres of power are accounted for. In this manuscript we outline a new Horizon project, FEAST, that aims to use multilevel governance approaches across vertical and horizontal spheres of governance to realize constructive food democracy. We envisage this as a means to inform just processes that can be used to design and implement policies, in line with food democracy, to facilitate transitions to “Win–Win–Win–Win” food systems across Europe that makes it easy for every European to eat a healthy and sustainable diet.

Published
2022
Full Text
View/download PDF

7. 523 - Efficacy and safety of amlitelimab (an anti-OX40 ligand antibody) in patients with moderate-to-severe atopic dermatitis: 24-week results from a phase 2b trial (STREAM-AD)

Author

Weidinger, Stephan, primary, Blauvelt, Andrew, additional, Papp, Kim, additional, Reich, Adam, additional, Lee, Chih-Hung, additional, Worm, Margitta, additional, Lynde, Charles, additional, Kataoka, Yoko, additional, Foley, Peter, additional, Weber, Christine, additional, Wong, Wanling, additional, Hurbin, Fabrice, additional, Rynkiewicz, Natalie, additional, Yen, Karl, additional, Wei, Xiaodan, additional, O’Malley, John T, additional, and Bernigaud, Charlotte, additional

Published
2024
Full Text
View/download PDF

11. Tumor-Specific Imaging with Angiostamp800 or Bevacizumab-IRDye 800CW Improves Fluorescence-Guided Surgery over Indocyanine Green in Peritoneal Carcinomatosis

Author

Véronique Josserand, Claire Bernard, Thierry Michy, Mélanie Guidetti, Julien Vollaire, Jean-Luc Coll, and Amandine Hurbin

Subjects
fluorescence-guided surgery, peritoneal carcinomatosis, indocyanine green, Bevacizumab-IRDye 800CW, Angiostamp800, bioluminescence imaging, Biology (General), QH301-705.5
Abstract

Complete surgical removal of lesions improves survival of peritoneal carcinomatosis and can be enhanced by intraoperative near-infrared fluorescence imaging. Indocyanine green (ICG) is the only near-infrared fluorescent dye approved for clinical use, but it lacks specificity for tumor cells, highlighting the need for tumor-selective targeting agents. We compared the tumor-specific near-infrared fluorescent probes Bevacizumab-IRDye 800CW and Angiostamp800, which target tumor angiogenesis and cancer cells, to ICG for fluorescence-guided surgery in peritoneal carcinomatosis of ovarian origin. The probes were administered to mice with orthotopic peritoneal carcinomatosis prior to conventional and fluorescence-guided surgery. The influence of neoadjuvant chemotherapy was also assessed. Conventional surgery removed 88.0 ± 1.2% of the total tumor load in mice. Fluorescence-guided surgery allowed the resection of additional nodules, enhancing the total tumor burden resection by 9.8 ± 0.7%, 8.5 ± 0.8%, and 3.9 ± 1.2% with Angiostamp800, Bevacizumab-IRDye 800CW and ICG, respectively. Interestingly, among the resected nodules, 15% were false-positive with ICG, compared to only 1.4% with Angiostamp800 and 3.5% with Bevacizumab-IRDye 800CW. Furthermore, conventional surgery removed only 69.0 ± 3.9% of the total tumor burden after neoadjuvant chemotherapy. Fluorescence-guided surgery with Angiostamp800 and Bevacizumab-IRDye 800CW increased the total tumor burden resection to 88.7 ± 4.3%, whereas ICG did not improve surgery at all. Bevacizumab-IRDye 800CW and Angiostamp800 better detect ovarian tumors and metastases than the clinically used fluorescent tracer ICG, and can help surgeons completely remove tumors, especially after surgery neoadjuvant chemotherapy.

Published
2022
Full Text
View/download PDF

16. Serum IGF1 is a prognostic marker for resistance to targeted therapies and a predictive marker for anti-IGF1R therapy in melanoma

Author

Ferrer, Camila Castillo, primary, Marguet, Théo, additional, Vanwonterghem, Laetitia, additional, Erbek, Sule, additional, Chuffart, Florent, additional, Mouret, Stéphane, additional, Messai, Sabiha Trabelsi, additional, Gauchez, Anne-Sophie, additional, Coll, Jean-Luc, additional, Charles, Julie, additional, Hurbin, Amandine, additional, and Martel-Frachet, Véronique, additional

Published
2023
Full Text
View/download PDF

19. Suppl. Movie 2 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Prunier, Chloé, primary, Josserand, Véronique, primary, Vollaire, Julien, primary, Beerling, Evelyne, primary, Petropoulos, Christos, primary, Destaing, Olivier, primary, Montemagno, Christopher, primary, Hurbin, Amandine, primary, Prudent, Renaud, primary, de Koning, Leanne, primary, Kapur, Reuben, primary, Cohen, Pascale A., primary, Albiges-Rizo, Corinne, primary, Coll, Jean-Luc, primary, van Rheenen, Jacco, primary, Billaud, Marc, primary, and Lafanechère, Laurence, primary

Published
2023
Full Text
View/download PDF

20. Supp. Figure 3 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Prunier, Chloé, primary, Josserand, Véronique, primary, Vollaire, Julien, primary, Beerling, Evelyne, primary, Petropoulos, Christos, primary, Destaing, Olivier, primary, Montemagno, Christopher, primary, Hurbin, Amandine, primary, Prudent, Renaud, primary, de Koning, Leanne, primary, Kapur, Reuben, primary, Cohen, Pascale A., primary, Albiges-Rizo, Corinne, primary, Coll, Jean-Luc, primary, van Rheenen, Jacco, primary, Billaud, Marc, primary, and Lafanechère, Laurence, primary

Published
2023
Full Text
View/download PDF

21. Supp. Figure 4 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Prunier, Chloé, primary, Josserand, Véronique, primary, Vollaire, Julien, primary, Beerling, Evelyne, primary, Petropoulos, Christos, primary, Destaing, Olivier, primary, Montemagno, Christopher, primary, Hurbin, Amandine, primary, Prudent, Renaud, primary, de Koning, Leanne, primary, Kapur, Reuben, primary, Cohen, Pascale A., primary, Albiges-Rizo, Corinne, primary, Coll, Jean-Luc, primary, van Rheenen, Jacco, primary, Billaud, Marc, primary, and Lafanechère, Laurence, primary

Published
2023
Full Text
View/download PDF

22. Prunier et al. Supplementary information from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Prunier, Chloé, primary, Josserand, Véronique, primary, Vollaire, Julien, primary, Beerling, Evelyne, primary, Petropoulos, Christos, primary, Destaing, Olivier, primary, Montemagno, Christopher, primary, Hurbin, Amandine, primary, Prudent, Renaud, primary, de Koning, Leanne, primary, Kapur, Reuben, primary, Cohen, Pascale A., primary, Albiges-Rizo, Corinne, primary, Coll, Jean-Luc, primary, van Rheenen, Jacco, primary, Billaud, Marc, primary, and Lafanechère, Laurence, primary

Published
2023
Full Text
View/download PDF

23. Supp. Figure 2 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Prunier, Chloé, primary, Josserand, Véronique, primary, Vollaire, Julien, primary, Beerling, Evelyne, primary, Petropoulos, Christos, primary, Destaing, Olivier, primary, Montemagno, Christopher, primary, Hurbin, Amandine, primary, Prudent, Renaud, primary, de Koning, Leanne, primary, Kapur, Reuben, primary, Cohen, Pascale A., primary, Albiges-Rizo, Corinne, primary, Coll, Jean-Luc, primary, van Rheenen, Jacco, primary, Billaud, Marc, primary, and Lafanechère, Laurence, primary

Published
2023
Full Text
View/download PDF

24. Suppl. Movie 3 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Prunier, Chloé, primary, Josserand, Véronique, primary, Vollaire, Julien, primary, Beerling, Evelyne, primary, Petropoulos, Christos, primary, Destaing, Olivier, primary, Montemagno, Christopher, primary, Hurbin, Amandine, primary, Prudent, Renaud, primary, de Koning, Leanne, primary, Kapur, Reuben, primary, Cohen, Pascale A., primary, Albiges-Rizo, Corinne, primary, Coll, Jean-Luc, primary, van Rheenen, Jacco, primary, Billaud, Marc, primary, and Lafanechère, Laurence, primary

Published
2023
Full Text
View/download PDF

25. Supp. Figure 1 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Prunier, Chloé, primary, Josserand, Véronique, primary, Vollaire, Julien, primary, Beerling, Evelyne, primary, Petropoulos, Christos, primary, Destaing, Olivier, primary, Montemagno, Christopher, primary, Hurbin, Amandine, primary, Prudent, Renaud, primary, de Koning, Leanne, primary, Kapur, Reuben, primary, Cohen, Pascale A., primary, Albiges-Rizo, Corinne, primary, Coll, Jean-Luc, primary, van Rheenen, Jacco, primary, Billaud, Marc, primary, and Lafanechère, Laurence, primary

Published
2023
Full Text
View/download PDF

26. Supp. Figure 5 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Prunier, Chloé, primary, Josserand, Véronique, primary, Vollaire, Julien, primary, Beerling, Evelyne, primary, Petropoulos, Christos, primary, Destaing, Olivier, primary, Montemagno, Christopher, primary, Hurbin, Amandine, primary, Prudent, Renaud, primary, de Koning, Leanne, primary, Kapur, Reuben, primary, Cohen, Pascale A., primary, Albiges-Rizo, Corinne, primary, Coll, Jean-Luc, primary, van Rheenen, Jacco, primary, Billaud, Marc, primary, and Lafanechère, Laurence, primary

Published
2023
Full Text
View/download PDF

27. Supp. Figure 7 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Prunier, Chloé, primary, Josserand, Véronique, primary, Vollaire, Julien, primary, Beerling, Evelyne, primary, Petropoulos, Christos, primary, Destaing, Olivier, primary, Montemagno, Christopher, primary, Hurbin, Amandine, primary, Prudent, Renaud, primary, de Koning, Leanne, primary, Kapur, Reuben, primary, Cohen, Pascale A., primary, Albiges-Rizo, Corinne, primary, Coll, Jean-Luc, primary, van Rheenen, Jacco, primary, Billaud, Marc, primary, and Lafanechère, Laurence, primary

Published
2023
Full Text
View/download PDF

28. Data from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Prunier, Chloé, primary, Josserand, Véronique, primary, Vollaire, Julien, primary, Beerling, Evelyne, primary, Petropoulos, Christos, primary, Destaing, Olivier, primary, Montemagno, Christopher, primary, Hurbin, Amandine, primary, Prudent, Renaud, primary, de Koning, Leanne, primary, Kapur, Reuben, primary, Cohen, Pascale A., primary, Albiges-Rizo, Corinne, primary, Coll, Jean-Luc, primary, van Rheenen, Jacco, primary, Billaud, Marc, primary, and Lafanechère, Laurence, primary

Published
2023
Full Text
View/download PDF

29. Suppl. Movie 1 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Prunier, Chloé, primary, Josserand, Véronique, primary, Vollaire, Julien, primary, Beerling, Evelyne, primary, Petropoulos, Christos, primary, Destaing, Olivier, primary, Montemagno, Christopher, primary, Hurbin, Amandine, primary, Prudent, Renaud, primary, de Koning, Leanne, primary, Kapur, Reuben, primary, Cohen, Pascale A., primary, Albiges-Rizo, Corinne, primary, Coll, Jean-Luc, primary, van Rheenen, Jacco, primary, Billaud, Marc, primary, and Lafanechère, Laurence, primary

Published
2023
Full Text
View/download PDF

30. Supp. Figure 6 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Prunier, Chloé, primary, Josserand, Véronique, primary, Vollaire, Julien, primary, Beerling, Evelyne, primary, Petropoulos, Christos, primary, Destaing, Olivier, primary, Montemagno, Christopher, primary, Hurbin, Amandine, primary, Prudent, Renaud, primary, de Koning, Leanne, primary, Kapur, Reuben, primary, Cohen, Pascale A., primary, Albiges-Rizo, Corinne, primary, Coll, Jean-Luc, primary, van Rheenen, Jacco, primary, Billaud, Marc, primary, and Lafanechère, Laurence, primary

Published
2023
Full Text
View/download PDF

33. Prunier et al. Supplementary information from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Laurence Lafanechère, Marc Billaud, Jacco van Rheenen, Jean-Luc Coll, Corinne Albiges-Rizo, Pascale A. Cohen, Reuben Kapur, Leanne de Koning, Renaud Prudent, Amandine Hurbin, Christopher Montemagno, Olivier Destaing, Christos Petropoulos, Evelyne Beerling, Julien Vollaire, Véronique Josserand, and Chloé Prunier

Abstract

Supplementary information, i.e. suppplementary table, supplemenatry figures and movies legends and supplementary materiel and methods

Published
2023
Full Text
View/download PDF

34. Supp. Figure 1 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Laurence Lafanechère, Marc Billaud, Jacco van Rheenen, Jean-Luc Coll, Corinne Albiges-Rizo, Pascale A. Cohen, Reuben Kapur, Leanne de Koning, Renaud Prudent, Amandine Hurbin, Christopher Montemagno, Olivier Destaing, Christos Petropoulos, Evelyne Beerling, Julien Vollaire, Véronique Josserand, and Chloé Prunier

Abstract

Analysis of LIMK1 expression in different breast cancer cell lines.

Published
2023
Full Text
View/download PDF

35. Suppl. Movie 3 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Laurence Lafanechère, Marc Billaud, Jacco van Rheenen, Jean-Luc Coll, Corinne Albiges-Rizo, Pascale A. Cohen, Reuben Kapur, Leanne de Koning, Renaud Prudent, Amandine Hurbin, Christopher Montemagno, Olivier Destaing, Christos Petropoulos, Evelyne Beerling, Julien Vollaire, Véronique Josserand, and Chloé Prunier

Abstract

MDA-MB-231 Dendra2 tumors followed by intravital microscopy after 8 days of Pyr1 treatment

Published
2023
Full Text
View/download PDF

36. Supp. Figure 5 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Laurence Lafanechère, Marc Billaud, Jacco van Rheenen, Jean-Luc Coll, Corinne Albiges-Rizo, Pascale A. Cohen, Reuben Kapur, Leanne de Koning, Renaud Prudent, Amandine Hurbin, Christopher Montemagno, Olivier Destaing, Christos Petropoulos, Evelyne Beerling, Julien Vollaire, Véronique Josserand, and Chloé Prunier

Abstract

RPPA results of tubulin acetylation, tubulin detyrosination and cofilin phosphorylation levels in tumors of mice treated with vehicle, Pyr1 and PTX

Published
2023
Full Text
View/download PDF

37. Data from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Laurence Lafanechère, Marc Billaud, Jacco van Rheenen, Jean-Luc Coll, Corinne Albiges-Rizo, Pascale A. Cohen, Reuben Kapur, Leanne de Koning, Renaud Prudent, Amandine Hurbin, Christopher Montemagno, Olivier Destaing, Christos Petropoulos, Evelyne Beerling, Julien Vollaire, Véronique Josserand, and Chloé Prunier

Abstract

LIM kinases (LIMK) are emerging targets for cancer therapy, and they function as network hubs to coordinate actin and microtubule dynamics. When LIMKs are inhibited, actin microfilaments are disorganized and microtubules are stabilized. Owing to their stabilizing effect on microtubules, LIMK inhibitors may provide a therapeutic strategy to treat taxane-resistant cancers. In this study, we investigated the effect of LIMK inhibition on breast tumor development and on paclitaxel-resistant tumors, using a novel selective LIMK inhibitor termed Pyr1. Treatment of breast cancer cells, including paclitaxel-resistant cells, blocked their invasion and proliferation in vitro and their growth in vivo in tumor xenograft assays. The tumor-invasive properties of Pyr1 were investigated in vivo by intravital microscopy of tumor xenografts. A striking change of cell morphology was observed with a rounded phenotype arising in a subpopulation of cells, while other cells remained elongated. Notably, although Pyr1 decreased the motility of elongated cells, it increased the motility of rounded cells in the tumor. Pyr1 administration prevented the growth of metastasis but not their spread. Overall, our results provided a preclinical proof of concept concerning how a small-molecule inhibitor of LIMK may offer a strategy to treat taxane-resistant breast tumors and metastases. Cancer Res; 76(12); 3541–52. ©2016 AACR.

Published
2023
Full Text
View/download PDF

38. Supp. Figure 2 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Laurence Lafanechère, Marc Billaud, Jacco van Rheenen, Jean-Luc Coll, Corinne Albiges-Rizo, Pascale A. Cohen, Reuben Kapur, Leanne de Koning, Renaud Prudent, Amandine Hurbin, Christopher Montemagno, Olivier Destaing, Christos Petropoulos, Evelyne Beerling, Julien Vollaire, Véronique Josserand, and Chloé Prunier

Abstract

Effect of PTX on the viability of breast cell lines.

Published
2023
Full Text
View/download PDF

39. Supp. Figure 4 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Laurence Lafanechère, Marc Billaud, Jacco van Rheenen, Jean-Luc Coll, Corinne Albiges-Rizo, Pascale A. Cohen, Reuben Kapur, Leanne de Koning, Renaud Prudent, Amandine Hurbin, Christopher Montemagno, Olivier Destaing, Christos Petropoulos, Evelyne Beerling, Julien Vollaire, Véronique Josserand, and Chloé Prunier

Abstract

Pharmacokinetic analysis of Pyr1 and its metabolite M1

Published
2023
Full Text
View/download PDF

40. Supp. Figure 3 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Laurence Lafanechère, Marc Billaud, Jacco van Rheenen, Jean-Luc Coll, Corinne Albiges-Rizo, Pascale A. Cohen, Reuben Kapur, Leanne de Koning, Renaud Prudent, Amandine Hurbin, Christopher Montemagno, Olivier Destaing, Christos Petropoulos, Evelyne Beerling, Julien Vollaire, Véronique Josserand, and Chloé Prunier

Abstract

Weight and behavior monitoring of mice used in the TS/A-pGL3 xenografts experiment

Published
2023
Full Text
View/download PDF

41. Suppl. Movie 1 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Laurence Lafanechère, Marc Billaud, Jacco van Rheenen, Jean-Luc Coll, Corinne Albiges-Rizo, Pascale A. Cohen, Reuben Kapur, Leanne de Koning, Renaud Prudent, Amandine Hurbin, Christopher Montemagno, Olivier Destaing, Christos Petropoulos, Evelyne Beerling, Julien Vollaire, Véronique Josserand, and Chloé Prunier

Abstract

FRAP analysis of actin dynamics in invadopodia treated with vehicle or Pyr1

Published
2023
Full Text
View/download PDF

42. Supp. Figure 6 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Laurence Lafanechère, Marc Billaud, Jacco van Rheenen, Jean-Luc Coll, Corinne Albiges-Rizo, Pascale A. Cohen, Reuben Kapur, Leanne de Koning, Renaud Prudent, Amandine Hurbin, Christopher Montemagno, Olivier Destaing, Christos Petropoulos, Evelyne Beerling, Julien Vollaire, Véronique Josserand, and Chloé Prunier

Abstract

Pyr1 effect on tumor cell density

Published
2023
Full Text
View/download PDF

43. Suppl. Movie 2 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Laurence Lafanechère, Marc Billaud, Jacco van Rheenen, Jean-Luc Coll, Corinne Albiges-Rizo, Pascale A. Cohen, Reuben Kapur, Leanne de Koning, Renaud Prudent, Amandine Hurbin, Christopher Montemagno, Olivier Destaing, Christos Petropoulos, Evelyne Beerling, Julien Vollaire, Véronique Josserand, and Chloé Prunier

Abstract

MDA-MB-231 Dendra2 tumors followed by intravital microscopy after 8 days of vehicle treatment

Published
2023
Full Text
View/download PDF

44. Supp. Figure 7 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers

Author

Laurence Lafanechère, Marc Billaud, Jacco van Rheenen, Jean-Luc Coll, Corinne Albiges-Rizo, Pascale A. Cohen, Reuben Kapur, Leanne de Koning, Renaud Prudent, Amandine Hurbin, Christopher Montemagno, Olivier Destaing, Christos Petropoulos, Evelyne Beerling, Julien Vollaire, Véronique Josserand, and Chloé Prunier

Abstract

In vivo analysis of the Pyr1 effect on LIMKs activity markers

Published
2023
Full Text
View/download PDF

46. Transitions to food democracy through multilevel governance

Author

Jani, Anant, primary, Exner, Andreas, additional, Braun, Reiner, additional, Braun, Brigitte, additional, Torri, Luisa, additional, Verhoeven, Sofie, additional, Murante, Anna Maria, additional, Van Devijvere, Stefanie, additional, Harrington, Janas, additional, Ochoa, Amalia, additional, Marchiori, Giorgia Dalla Libera, additional, Defranceschi, Peter, additional, Bunker, Aditi, additional, Bärnighausen, Till, additional, Sanz Sanz, Esther, additional, Napoléone, Claude, additional, Verger, Eric O., additional, Schader, Christian, additional, Röklov, Joacim, additional, Stegeman, Ingrid, additional, Tonello, Samuele, additional, Pederson, Robert, additional, Kristensen, Niels Heine, additional, Smits, Tim, additional, Wascher, Dirk, additional, Voshol, Peter, additional, Kaptejins, Annemarie, additional, Nesrallah, Samantha, additional, Kjørven, Olav, additional, DeClerck, Fabrice, additional, Biella, Cristina, additional, Gjorgjioska, Marija Adela, additional, Tomicic, Ana, additional, Ferreira Oliveira, Ana Teresa, additional, Bracco, Stefania, additional, Estevens, Sandra, additional, Rossi, Luigi, additional, Laister, Günther, additional, Różalska, Aleksandra, additional, Jankuloski, Borche, additional, Hurbin, Christophe, additional, Jannic, Maýlis, additional, Steel, Fiona, additional, Manbaliu, Ewoud, additional, De Jager, Karin, additional, Sfetsos, Athanasios, additional, Konstantopoulou, Maria, additional, Kapetanakis, Pavlos-Alexandro, additional, Hickersberger, Michaela, additional, Chiffard, Elsa, additional, and Woollhead, Carina, additional

Published
2022
Full Text
View/download PDF

49. Endothelial‐protective effects of a G‐protein‐biased sphingosine‐1 phosphate receptor‐1 agonist, SAR247799, in type‐2 diabetes rats and a randomized placebo‐controlled patient trial

Author

Theresa Herbrand, Bruno Poirier, Philip Janiak, Anthony J. Muslin, Paul Deutsch, Hans Veit Coester, Xavier Benain, Lionel Hovsepian, Luc Bergougnan, Maria Francesca Evaristi, Ashfaq Parkar, Jorge Arrubla, Rania Boiron, Grit Andersen, Olivier Vitse, Agnes Tardat, Roberto Sansone, Stephane Kirkesseli, Christian Heiss, Radzik Davide, Leona Plum-Mörschel, Marcel Ermer, and Fabrice Hurbin

Subjects
Agonist, medicine.medical_specialty, Brachial Artery, endothelium, Endothelium, medicine.drug_class, Sildenafil, medicine.medical_treatment, Sphingosine-1-phosphate receptor, Renal function, SAR247799, Type 2 diabetes, Pharmacology, flow‐mediated dilation, Placebo, 030226 pharmacology & pharmacy, Gastroenterology, Phosphates, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, GTP-Binding Proteins, Sphingosine, Internal medicine, Diabetes mellitus, medicine, Animals, Humans, Pharmacology (medical), 030212 general & internal medicine, Endothelial dysfunction, Desensitization (medicine), sphingosine‐1 phosphate receptor‐1, diabetes, business.industry, Original Articles, medicine.disease, Rats, Rats, Zucker, Vasodilation, Blood pressure, medicine.anatomical_structure, Diabetes Mellitus, Type 2, chemistry, Original Article, Endothelium, Vascular, business
Abstract

AIMS SAR247799 is a G-protein-biased sphingosine-1 phosphate receptor-1 (S1P1 ) agonist designed to activate endothelial S1P1 and provide endothelial-protective properties, while limiting S1P1 desensitization and consequent lymphocyte-count reduction associated with higher doses. The aim was to show whether S1P1 activation can promote endothelial effects in patients and, if so, select SAR247799 doses for further clinical investigation. METHODS Type-2 diabetes patients, enriched for endothelial dysfunction (flow-mediated dilation, FMD

Published
2020
Full Text
View/download PDF

50. Efficacy and safety of amlitelimab (an anti-OX40 ligand antibody) in patients with moderate-to-severe atopic dermatitis: 24-week results from a phase 2b trial (STREAM-AD).

Author

Weidinger, Stephan, Blauvelt, Andrew, Papp, Kim, Reich, Adam, Chih-Hung Lee, Worm, Margitta, Lynde, Charles, Yoko Kataoka, Foley, Peter, Weber, Christine, Wanling Wong, Hurbin, Fabrice, Rynkiewicz, Natalie, Yen, Karl, Xiaodan Wei, O'Malley, John T., and Bernigaud, Charlotte

Subjects
ATOPIC dermatitis, TREATMENT effectiveness, MONOCLONAL antibodies, IMMUNOGLOBULINS, LIGAND binding (Biochemistry)
Abstract

Introduction/Background Targeting and binding OX40 ligand (OX40L) expressed on antigen-presenting cells may inhibit the persistent immune response that drives atopic dermatitis (AD) pathophysiology. Amlitelimab (SAR445229; KY1005) is a potential first-in-class, fully human, non-depleting anti-OX40L monoclonal antibody that blocks OX40L-OX40 interactions and has shown efficacy and an acceptable safety profile in a Phase 2a trial in adults with moderate-to-severe AD. Here, we present 24-week efficacy and safety results (Part 1) from an ongoing dose-ranging Phase 2b trial. The study remains blinded to individual patient data (Part 2 ongoing). Objectives: To evaluate the efficacy and safety of amlitelimab in adults with moderate-to-severe AD. Methods: STREAM-AD (NCT05131477) is a 52-week, randomised, double-blinded, placebo-controlled Phase 2b monotherapy trial. This study is designed with 2 parts (double-blind throughout): a 24-week treatment period (Part 1, completed and presented here) and a 36-week maintenance/withdrawal period (Part 2, ongoing). Adults (18 to <75 years; n=390) with moderate-to-severe AD were randomised 1:1:1:1:1 to receive subcutaneous amlitelimab Q4W (250 mg with 500 mg loading dose [LD], n=77; 250 mg without LD, n=78; 125 mg without LD, n=77; or 62.5 mg without LD, n=79) or placebo Q4W (n=79). The primary endpoint was percentage change in Eczema Area and Severity Index (EASI) from baseline at Week 16. Key secondary endpoints included percentage change in EASI at Week 24 and percentage of patients with at least 75% reduction from baseline in EASI (EASI-75), percentage of patients with Investigator Global Assessment response of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points (IGA 0/1), and proportion of patients with a weekly average reduction of Peak Pruritus Numerical Rating Scale (PP-NRS) ≥4 points from baseline. The primary efficacy analysis included all randomised patients who completed Week 24 or discontinued treatment or study prior to Week 24 visit (n=390), whereas the safety analysis included all treated patients (n=388). Results: Treatment with amlitelimab resulted in statistically significant improvements in percentage change in EASI from baseline to Week 16 compared to placebo for all four doses studied. The 250 mg with LD group had the numerically highest response versus placebo at Week 16, with a least-squares mean change from baseline of -32.1% (95% CI: -43.9, -20.3; P<0.0001); the remaining groups without LD had the following responses versus placebo: 250 mg, -27.3 (95% CI: -39.1, -15.6; P<0.0001); 125 mg, -22.2 (95% CI: -34.0, -10.4; P=0.0002); and 62.5 mg, -30.2 (95% CI: -41.9, -18.5; P<0.0001). There were also clinically meaningful improvements in all key secondary efficacy outcome measures, with all amlitelimab dose groups demonstrating nominally significant (P<0.05) efficacy versus placebo for EASI-75, IGA 0/1, and PP-NRS =4, except 250 mg (no LD) in IGA 0/1 at Week 16 (P=0.0562). Continued improvements were generally observed through Week 24 in primary and key secondary efficacy outcomes. Amlitelimab was well tolerated across all dose groups, with no safety concerns identified. Conclusions: In this dose-ranging Phase 2b trial of amlitelimab in adults with moderate-to-severe AD, amlitelimab demonstrated clinically meaningful efficacy over 24 weeks with an acceptable safety profile across all four dose groups. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results